PT  - JOURNAL ARTICLE
AU  - Mosley, Mary
ED  - Arnold, Dirk
TI  - Active Maintenance Therapy Prolongs TFS and PFS in CRC
DP  - 2014 Nov 01
TA  - MD Conference Express
PG  - 15--15
VI  - 14
IP  - 22
4099  - http://mdc.sagepub.com/content/14/22/15.1.short
4100  - http://mdc.sagepub.com/content/14/22/15.1.full
AB  - One of the current standards of care for the first-line therapy of metastatic colorectal cancer (mCRC) is combination chemotherapy with fluoropyrimidine (FP) and oxaliplatin (OX) plus the angiogenesis inhibitor, bevacizumab (BEV). The Phase 3 AIO KRK 0207 study [NCT00973609] showed that active maintenance therapy with FP+BEV or BEV alone, compared with no treatment, prolonged the time-to-failure of strategy and progression-free survival in patients with mCRC after induction treatment [Arnold D et al. Ann Oncol. 2014 (abstr O-0027); J Clin Oncol. 2014 (abstr 3503)].